ANZCTR search results

Stimulant medication can be associated with slowing of growth in children with attention deficit hyperactivity disorder (ADHD), possibly by appetite suppression mediated by hormones such as leptin and ghrelin. Twelve healthy adult volunteers will have fasting blood tests for leptin, ghrelin, insulin and glucose, with these tests repeated after a meal. This will be done twice, once on medication (dexamphetamine or methylphenidate) and once on placebo. The effect of medication on food intake and alertness will be tested, together with subjects’ assessments of appetite and medication side effects.

The major concern for women on long term follow up after breast cancer has been treated, is fear of the reoccurrence of disease. This study will test a new strategy to prevent disease reocurrence and death due to breast cancer. The purpose of the study is to find out whether later re-treatment of participants with adjuvant letrozole therapy can prevent or delay new breast cancers from reoccurring in postmenopausal women previously treated with adjuvant endocrine therapy

Individuals with symptomatic CAD probably constitute a population at high risk for accelerated decline in cognitive function, because of the overlap between Alzheimer’s disease, vascular dementia and the risk factors for both. Appropriate clinical decision-making for these patients depends on the accurate understanding of the prevalence of prodromal conditions such as MCI, the incidence of PPCD and how they affect the rate of conversion to dementia in these patients.

This study compares metformin (current first-line medication) to rosiglitazone (a newer diabetic medication currently approved for combination use). Whilst there is good evidence for the benefits of rosiglitazone use in other populations, in light of the known weight gain effects of pioglitazone we believe further assessment is required in Indigenous Australians (in whom there is a strong predisposition for central fat deposition). This study will provide evidence regarding the medication appropirate for first line medication in Type 2 diabetes in this high risk population. This study will assist clinicians to make evidenced-based decisions regarding initial medical management of those with Type 2 diabetes (where there is currently a gap in evidence).

This is a novel study that investigates the benefits of NAC treatment in unipolar depression. Based on previous literature that reported deficits of this antioxidant in the brains of people with schizophrenia and bipolar disorder, the study postulates the deficits in unipolar depression patients. This trial involves adjunctive treatment where patients are received either NAC or placebo on top of their usual medication for a duration of 8 weeks.

Obesity and type 2 diabetes increase the risk of heart, kidney and other disease. A process called oxidative stress is thought to be critical in triggering metabolic changes found in both obesity and diabetes, and thus is a major cause of developing complications from these conditions. The role of weight loss in reducing markers of oxidative stress has not been compared in obese people with and without diabetes. We predict that weight loss in obese patients with diabetes will reduce oxidative stress, and improve kidney and heart dysfunction, to a greater extent than in obese patients without diabetes.

Primary purpose of the study is to investigate whether antenatal hypnosis decreases the suffering associated with nausea and vomiting of pregnancy

It is hypothesized that soluble fibre from oats will increase satiety, when consumed as part of an energy-controlled diet. The increased satiety will allow improved compliance with dietary regimens and result in increased weight loss in overweight individuals compared with control subjects on energy restriction alone.

This study will be an open, non-randomised, clinical phase 2 trial which will involve 30 women diagnosed with Uterine Serous Papillary Cancer. We will investigate the effect of four cycles of Paclitaxel / Carboplatin, followed by whole pelvic external beam radiotherapy to a standard pelvis field (50.4 Gy) with or without a para-aortic boost with respect to safety and efficacy of treatment, and patterns of recurrence.

The purpose of the study is to determine whether BG00012 is effective in reducing the proportion of patients experiencing a clinical relapse at 2 years compared to placebo in patients with relapsing remitting multiple sclerosis. Two different doses of BG00012 will be compared to placebo. Patients will be randomised to one of 3 groups in a 1:1:1 ratio: Group 1 will receive 480 mg daily orally via 2 capsules 3 times daily. Each capsule will contain either 120 mg BG00012 or placebo. Group 2 will receive 720 mg daily orally via 2 capsules 3 times daily. Each capsule will contain 120 mg BG00012. Group 3 will receive placebo orally via 2 capsules 3 times daily. Patients will have the option of switching to open label Avonex (interferon beta-1a) if they experience relapse after 24 weeks and have completed 48 weeks of double blind treatment, OR they experience disability progression sustained for 12 weeks at any time.